MedPath

Simbec-Orion and Avance Clinical Form Strategic Global CRO Partnership to Enhance Clinical Trial Capabilities

• UK-based Simbec-Orion and Australian-headquartered Avance Clinical have signed a Memorandum of Understanding to create a unified global clinical research organization spanning Europe, Asia-Pacific, and North America.

• The partnership combines Simbec-Orion's 50-year expertise in Clinical Pharmacology, Oncology, and Rare Diseases with Avance Clinical's 30-year track record across 250+ indications.

• This strategic alliance enables seamless execution of global clinical trials from Phase I to III, offering clients expanded geographical reach and integrated research services while maintaining FDA and EMA data standards.

The clinical research landscape is set to transform as two prominent contract research organizations (CROs) forge a strategic partnership to enhance their global capabilities. Simbec-Orion, a UK-based CRO with nearly 50 years of experience, and Avance Clinical, Australia's largest premium full-service CRO, have solidified their collaboration through a Memorandum of Understanding (MOU).
The partnership creates a unified platform spanning 34 countries across the UK, Europe, North America, and Asia-Pacific regions, offering comprehensive clinical research services from First in Human studies to Phase III trials.

Expanded Service Portfolio and Global Reach

The alliance leverages both organizations' complementary strengths to provide an extensive range of services, including:
  • Project Management and Clinical Operations
  • Medical Monitoring and Regulatory Affairs
  • Data Management and Biostatistics
  • Quality Assurance and Pharmacovigilance
  • IMP Management and Central Lab Services
Simbec-Orion brings its MHRA Accredited Phase I Unit and specialized expertise in Clinical Pharmacology, Oncology, and Rare Diseases. The company's consultancy services extend to the preclinical stage, facilitating smooth transitions into clinical phases.

Enhanced Regional Capabilities

"This collaboration enhances our already robust capabilities in Australia, Asia, and the US," notes Yvonne Lungershausen, CEO of Avance Clinical. The partnership particularly strengthens Avance Clinical's presence in Europe and the UK while expanding Simbec-Orion's reach into the Asia-Pacific region.
Avance Clinical's 30-year experience across 250+ indications complements Simbec-Orion's extensive portfolio, ensuring delivery of clinical trial data that meets both FDA and EMA standards.

Strategic Benefits for Clients

Fabrice Chartier, CEO of Simbec-Orion, emphasizes the partnership's significance: "This partnership exemplifies the synergy between two agile, full-service CROs with a shared commitment to delivering tailored, high-quality clinical trial solutions. Together, we're poised to provide clients with a seamless, fully integrated approach to global clinical development."
The collaboration offers several key advantages:
  • Access to diverse patient populations across multiple regions
  • Unified CRO experience for complex clinical development programs
  • Streamlined trial execution through combined expertise
  • Maintenance of high-quality standards across all regions
  • Efficient trial outcomes through coordinated operations
This strategic partnership represents a significant development in the CRO sector, promising to enhance the efficiency and reach of clinical trials while maintaining the highest standards of research quality and data integrity.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Across Global Alliance Adopts Wemedoo's oomnia Platform to Transform Global Clinical Trial Management

Across Global Alliance has selected Wemedoo's oomnia® as its centralized clinical trial infrastructure, integrating essential functions like EDC, CTMS, RTSM, and eTMF into a unified platform across 90+ countries.
The strategic partnership aims to streamline clinical trial management, enhance real-time collaboration, and ensure regulatory compliance while eliminating inefficiencies from fragmented systems.

LabConnect and Australian Clinical Labs Form Strategic Alliance to Expand Clinical Trial Services in Asia-Pacific

LabConnect and Australian Clinical Labs' Specialised Trials have established a multi-year partnership to enhance clinical trial support services across Australia and the Asia-Pacific region.
The collaboration leverages ACL's extensive laboratory network and LabConnect's global expertise to support pharmaceutical trials from Phase 1 to Phase 4, strengthening their position in an $8 billion market.

ORIC Pharmaceuticals Announces Promising Early Data for ORIC-944 and Collaboration for ORIC-114

ORIC Pharmaceuticals reported encouraging early data from a Phase 1b trial of ORIC-944 combined with apalutamide in metastatic castration-resistant prostate cancer (mCRPC).
The company entered a clinical trial collaboration with Johnson & Johnson to evaluate ORIC-114 with amivantamab for first-line treatment of NSCLC with EGFR exon 20 insertion mutations.

HiRO and CHA University Bundang Medical Center Partner to Advance Global Clinical Trials

Harvest Integrated Research Organization (HiRO) and CHA University Bundang Medical Center (CBMC) have formed a strategic partnership to enhance global clinical trials.
The collaboration aims to streamline clinical trial processes, foster innovation, and drive advancements in healthcare research across phases I-IV.

ICPO Foundation and Munich Precision Oncology Partner to Establish Global Theranostics Centers

The ICPO Foundation and Munich Precision Oncology (MPO) have partnered to establish a pilot center in Garching, near Munich, to advance radiomolecular cancer treatments.
The Munich pilot center will serve as a functional demonstrator for ICPO, incorporating cutting-edge technology and setting new standards in cancer treatment.

Australia and UK Partner to Fund Clinical Trials Addressing Unmet Medical Needs

Australia and the UK are jointly funding clinical trials with A$30 million to address significant unmet clinical needs.
The funding supports platform trials that simultaneously assess multiple interventions for serious health conditions.

WELL Health and HEALWELL AI Expand Partnership to Enhance AI-Driven Clinical Trials in Canada

WELL Health and HEALWELL AI are expanding their strategic alliance to launch and manage clinical trial sites across WELL Health's Canadian clinics.
The partnership aims to provide end-to-end, AI-driven clinical trial services, from patient recruitment and trial execution to data analysis.

Anbogen and BeiGene Collaborate to Evaluate Combination Therapy in Colorectal Cancer

Anbogen and BeiGene will collaborate in a Phase II trial to evaluate Anbogen's ABT-301 combined with BeiGene's tislelizumab in metastatic colorectal cancer (mCRC) patients.
The trial targets patients with mismatch repair–proficient (pMMR) or microsatellite stable (MSS) mCRC, who do not typically respond to immune checkpoint inhibitors.

BioPharma Services Expands into Late-Stage Trials with AI Integration

BioPharma Services is expanding into late-stage patient trials by integrating Canadian Phase Onward (CPO), enhancing its clinical trial capabilities.
The integration allows BioPharma to offer comprehensive clinical trial services across all phases of drug development, becoming a full-service CRO.

NeuroSense Advances ALS Treatment with PrimeC Through Strategic Partnership

NeuroSense Therapeutics has entered into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, its proprietary treatment for amyotrophic lateral sclerosis (ALS), in key territories. The agreement includes substantial financial terms and retains NeuroSense's full rights to PrimeC in other territories.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy